Off-target toxicity has killed off one of Bolt Biotherapeutics’ lead programs. Rather than push BDC-2034 into the clinic, the immuno-oncology startup is winding down spending on the anti-tumor ...
Northfield, Ill.-based Medline will invest $20 million to expand its flush manufacturing plants in Wisconsin and New Jersey. The expansion will help broaden the company’s portfolio of SwabFlush ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback